【04/20更新】下落している(株)ジーエヌアイグループ【2160】、これからどうなる！？掲示板の反応まとめ。

何か、上場材料がポッ・・と場中に出そう！

多ハンのアホがまだまだいる。

売り煽りのヘタレ多ハン雑魚がいなくなった　笑
そろそろ勃起するやろ！

株価は下がってもohjのイジリ下がりまへん

キモい。

返信すんな阿呆

明日は全戻しにならなければ良いがね〜
さて、どうなるかな！

お前5日ルールも知らんのか勉強せいボケ。

報告書でてないのが問題だろ

明日？

下がるよ^ ^

Magnitude 5.7 earthquake offshore Chile

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

Chinese President Xi: Instabilities And Uncertainties Of The World Have Significantly Increased - Boao Forum

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

気文2160助かりますか？お願いします

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf
https://www.axcelead-hd.com/

19th of April, 2021
AXEL MARK Inc.
Axcelead, Inc.
AXEL MARK and Axcelead have Agreed to Cooperate in
Product Evaluation & Domestic Logistics of Molecular Diagnostics Field
AXEL MARK Inc. (President & CEO, Hiroshi Matsukawa, TSE Mothers:3624, “Axcel Mark”) and Axcelead, Inc.
(President & CEO, Tomoyuki Fujisawa, “Axcelead”) today announced that they have agreed on a collaborative
partnership in product evaluation & domestic logistics of molecular diagnostics field.
AXEL MARK has previously made the disclosure of "The 22nd Acquisition and Cancellation of Stock
Acquisition Rights and the 1st Notice Regarding Changes in Use of Funds for Unsecured Convertible Bonds
with Stock Acquisition Rights” on March 26 2021, announced about our new entry into the healthcare
business, and this press release is an announcement regarding to it. Please see the following materials for
the information on AXEL MARK's entry into the healthcare business.
○Disclosure on 26th March, 2021
https://contents.xj-
storage.jp/xcontents/AS02626/59834c81/8587/4459/9a33/c4a07164fcd9/140120210326485155.pdf
The market is undergoing rapid expansion due to the unprecedented global demand for COVID-19 testing
via molecular methods, but the other segments, including cancer and various infectious disease, are also
experiencing significant growth. The global market for molecular diagnostics is expected to reach to the value
of more than $12bn. by 2024. ※
“Molecular diagnostics” is the diagnostic and screening process of infectious disease, cancer, and genetic
disease by analyzing proteins and nucleic acid（DNA and RNA）molecules in tissue or body fluid.
Disease identification is being utilized not only in medical site but also in private companies and home
diagnosis as it leads to early detection and treatment of diseases, and new technologies are being actively
developed worldwide.
In addition to the conventional major chemical analysis equipment, reagents, and scientific service
companies, start-up companies are also promoting the development of new technology for molecular
diagnosis, and test kits with various features have been commercialized, and new products will continue to be
released in the market from now on.
Axcelead will evaluate promising new technologies in the field of molecular diagnosis of overseas ventures
that do not have commercial distribution to Japan, and AXEL MARK will acquire domestic commercialization
rights and develop appropriate business partners. We believe that this partnership can build the collaborative
value chain in the molecular diagnosis market.
Hereafter, both companies aim to contribute to improve people’s healthy life expectancy by promoting the
spread of new medical diagnosis technologies.
https://www.axcelead-hd.com/wp-content/uploads/2021/04/ENG_AXELMARK_AXCELEAD2021.04.19.pdf

GNI↑

U.S. RECOGNIZES DEEP ECONOMIC AND COMMERCIAL TIES BETWEEN JAPAN AND CHINA AND RESPECTS SUGA'S DESIRE TO WALK A CAREFUL COURSE - OFFICIAL

グミは頑張ってるのグニと言ったら全く…

グミと間違えてグニ買ったけどこっちもこっちでひでぇ
バイオやんけ…

イメージワンはGNIを思い出す

重要な発表まで株価上げ続けて、発表でもって滝行

GNI　完全に終了

GNI　おわった

GNI↑

バブグニ悲惨やな
バブグミとバブチームもぱっとしないし、バブターツなんて出来高400株とかどうすんのよ
バブ旛くらいやん

RBA Financial Stability Review

- Banks could handle a significant economic deterioration

- Office vacancies in Sydney and Melbourne near a 20-year high

- BBG

2160　GNI　逆行高

ID:7dXkkFsr=ビッグニップル

GNI

GNI↑